Related Experiment Video
Updated: Apr 14, 2026
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
Published on: November 29, 2024
Validation of a Novel Rodent Model to Test Anti-scarring Therapeutics
George Kokosis1, Jennifer E Bond1, Lei Chen2
1Division of Plastic and Reconstructive Surgery, Department of Surgery, Duke University Medical Center, Durham, NC.
Unlabelled:
Scar contracture is a debilitating disease that affects many people worldwide. There are currently no effective preventative medi- cal treatments. A pivotal step to attaining the goal of developing a treatment is the testing of anti-scarring agents in preclinical hierarchi- cal animal models of human scarring.
Methods:
A 2-cm x 2-cm, full- thickness, excisional wound was created in the rats' mid-scapular area. Three experiments were performed. The first experiment determined the optimal dressing in wound contraction. The second experiment de- veloped upon the results of the first experiment, and determined how anatomic site of osmotic pump implantation affected wound healing. The third experiment determined how the size of osmotic pump affect- ed wound healing. Wound healing parameters including rate of wound contraction, systemic and local toxicity, proliferation, collagen archi- tecture, and collagen production were assessed.
Results:
The results of the present study showed that covering the wound with TegadermTM (3M Health Care, St. Paul, MN) alone had the most linear wound con- traction rate with the smallest standard error of the mean. Implanta- tion of all osmotic pump sizes, when implanted intraperitoneally, was tolerated and did not interfere with wound healing. In contrast, sub- cutaneous implanted pumps caused significant discomfort in the rats.
Conclusion:
Implantation of an osmotic pump intraperitoneal in the rat excisional wound model, where the wound is covered with Tegaderm, provides for a reproducible, accurate, preclinical animal model to study anti-scar contracture treatments. .
Insights
Developing an effective preclinical model for scar contracture is crucial. This study established a reproducible rat model using Tegaderm dressings and intraperitoneal osmotic pumps for testing anti-scarring agents.
Area of Science:
- Biomedical Engineering
- Wound Healing Research
- Preclinical Animal Models
Background:
- Scar contracture is a significant global health issue with no current preventative medical treatments.
- Developing effective anti-scarring agents requires reliable preclinical models to test therapeutic strategies.
Purpose of the Study:
- To establish a reproducible and accurate preclinical animal model for evaluating anti-scarring agents.
- To optimize wound management and drug delivery parameters in a rat excisional wound model.
Main Methods:
- Created full-thickness excisional wounds in rats.
- Optimized wound dressings (Tegaderm) and osmotic pump implantation sites (intraperitoneal vs. subcutaneous).
- Assessed wound contraction rate, toxicity, proliferation, and collagen architecture.
Main Results:
- Tegaderm dressing alone demonstrated the highest linear wound contraction rate.
- Intraperitoneal osmotic pump implantation was well-tolerated and did not impede wound healing.
- Subcutaneous pump implantation caused significant discomfort in rats.
Conclusions:
- A rat excisional wound model covered with Tegaderm and utilizing intraperitoneal osmotic pumps provides a reproducible preclinical model.
- This model is suitable for the accurate study of anti-scar contracture treatments.
- Further research can utilize this optimized model to accelerate the development of scar contracture therapies.
